Mohamad Hussein

Steve Andresen1
Francisco Robert1
Learn More
Vorinostat (Zolinza), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. This review summarizes evidence on the use of(More)
This editorial marks the launch of a new online journal for surgical and medical oncology. The internet has produced a profound shift in the way in which clinicians, researchers and patients seek, interpret and utilise medical information and research. The launch of our journal comes at a time when these changes are in a rapid phase of development and(More)
BACKGROUND The timed-sequential chemotherapy regimen consisting of etoposide, mitoxantrone and cytarabine (EMA) is an effective therapy for relapsed or refractory acute myelogenous leukemia (AML). We postulated that granulocyte colony-stimulating factor (G-CSF) might enhance the cytotoxicity of EMA by increasing the proportion of leukemic blasts in S-phase.(More)
  • 1